ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
120.767,19
-1,73%
S&P 500
5.346,99
-0,11%
US Dollar vs BRL
5,3451
-0,02%
Bitcoin
69.300,24
-0,05%
Brent Oil
79,395
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Orgenesis Inc (ORGS)

  7. Orgenesis Inc (ORGS) Notícias

ORGS

Orgenesis (ORGS)

Orgenesis Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ORGS
DataHoraFonteTítuloCódigoCompanhia
06/06/202417:05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ORGSOrgenesis Inc
04/06/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ORGSOrgenesis Inc
31/05/202407:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ORGSOrgenesis Inc
24/05/202410:16Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ORGSOrgenesis Inc
21/05/202408:00GlobeNewswire Inc.Orgenesis Provides Business Update for the First Quarter of 2024NASDAQ:ORGSOrgenesis Inc
20/05/202417:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ORGSOrgenesis Inc
15/05/202417:01Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:ORGSOrgenesis Inc
06/05/202416:30Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ORGSOrgenesis Inc
06/05/202416:28Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ORGSOrgenesis Inc
06/05/202416:26Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ORGSOrgenesis Inc
15/04/202418:07GlobeNewswire Inc.Orgenesis Provides Year End Business UpdateNASDAQ:ORGSOrgenesis Inc
10/04/202413:00GlobeNewswire Inc.Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global AccessibilityNASDAQ:ORGSOrgenesis Inc
18/03/202409:30GlobeNewswire Inc.Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe ConferenceNASDAQ:ORGSOrgenesis Inc
13/03/202409:30GlobeNewswire Inc.Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic ExosomesNASDAQ:ORGSOrgenesis Inc
04/03/202410:30GlobeNewswire Inc.Orgenesis Inc. Announces $2.3 Million Private PlacementNASDAQ:ORGSOrgenesis Inc
29/02/202410:30GlobeNewswire Inc.Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP ManufacturingNASDAQ:ORGSOrgenesis Inc
31/01/202411:15GlobeNewswire Inc.Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to ClinicNASDAQ:ORGSOrgenesis Inc
08/01/202419:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ORGSOrgenesis Inc
08/01/202419:36Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ORGSOrgenesis Inc
14/11/202310:30GlobeNewswire Inc.Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TMNASDAQ:ORGSOrgenesis Inc
13/11/202318:15GlobeNewswire Inc.Orgenesis Provides Business Update for the Third Quarter of 2023NASDAQ:ORGSOrgenesis Inc
09/11/202309:41Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ORGSOrgenesis Inc
08/11/202311:00GlobeNewswire Inc.Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct OfferingNASDAQ:ORGSOrgenesis Inc
02/11/202309:00GlobeNewswire Inc.Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant FundingNASDAQ:ORGSOrgenesis Inc
30/10/202322:30GlobeNewswire Inc.Orgenesis Announces Withdrawal of Proposed Public OfferingNASDAQ:ORGSOrgenesis Inc
30/10/202317:07GlobeNewswire Inc.Orgenesis Announces Proposed Underwritten Public OfferingNASDAQ:ORGSOrgenesis Inc
21/09/202309:00GlobeNewswire Inc.CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United StatesNASDAQ:ORGSOrgenesis Inc
08/09/202317:05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ORGSOrgenesis Inc
06/09/202308:00GlobeNewswire Inc.Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service SupportNASDAQ:ORGSOrgenesis Inc
11/08/202308:00GlobeNewswire Inc.Orgenesis Provides Business Update for Second Quarter of 2023NASDAQ:ORGSOrgenesis Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ORGS

Seu Histórico Recente

BIT
UC5A59
Unicredit Bank
BIT
UB9FGR
Unicredit Bank
LSE
CLIP
Gx 1-3m Tbill
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados